Improving patient access to life-enhancing medications

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals.

We have a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world.

More about us Our capabilities
Female stretching

We offer patients better, safer & more accessible medicines.

View our products Explore our capabilities
Man looking in microscope

Capabilities

To improve patient access to life-enhancing prescription medications, Mayne Pharma offers a robust portfolio of branded and generic drugs in multiple therapeutic areas, including women's health, oncology, dermatology and cardiology.

Learn more
Pills

Contract services

Mayne Pharma has two full-service contract development and manufacturing organisations (CDMO) specialising in novel oral and topical dose forms providing pharmaceutical development, analytical testing and commercial manufacturing to over 100 clients worldwide. Our mission is to partner with clients to develop and deliver pharmaceutical products from “concept to commercialisation” to change the lives of patients around the globe:

Learn more

Sustainability

At Mayne Pharma, we recognise that we are part of a global community. As part of this community, we are committed to operating our business in a sustainable manner. We ensure our people are safe and well-supported, local communities prosper and the environment is well cared for so that it benefits future generations.

Learn more

For investors

More for investors

ASX: - AEST

  • Open
  • High
  • Low
  • Market Cap
  • Volume
  • 52 week

News & Events

View all

Mayne Pharma SA Employees email size_(c)kaycannliveshots-17

Mayne Pharma recipient of $4.8m Federal Government Grant

9 May 2022

Mayne Pharma Group Limited is pleased to announce that its application for a Federal Government Modern Manufacturing Initiative (MMI) Grant has been successful.

Learn more

Ms Ann Custin

Non Executive Director appointment

22 Mar 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Ann Custin has accepted an invitation to join the Board of Mayne Pharma, effective 23 March 2022.

Learn more

Financial,Data,Graph,Chart,,Vector,Illustration.,Abstract,Background,With,Graph

Mayne Pharma 2022 Half Year Results Media Release

25 Feb 2022

Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to support the launch of NEXTSTELLIS.

Learn more

Female looking into mirror

Mayne Pharma expands US dermatology portfolio

10 Feb 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has launched an authorised generic (AG) of one of the largest dermatology products in the United States.

Learn more

Dr Kathryn MacFarlane

Non Executive Director appointment and retirement

17 Jan 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Kathryn MacFarlane, PharmD, has accepted an invitation to join the Board of Mayne Pharma, effective 1 February 2022.

Learn more

female doctor with female patient

Mayne Pharma adds a generic PROTOPIC® to US portfolio

12 Jan 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of tacrolimus ointment, 0.1% in the United States

Learn more